Disease
35
4
4
15
Key Insights
Highlights
Success Rate
88% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
5.7%
2 terminated out of 35 trials
88.2%
+1.7% vs benchmark
11%
4 trials in Phase 3/4
27%
4 of 15 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 15 completed trials
Clinical Trials (35)
The Effect of a Mobile Game Application on Children With CRF
Diagnostic Reasoning With Customized GPT-4 Model
The Relationship of Hand Sensory and Strength Assessments with Functionality and Kinesiophobia in Individuals with Rheumatoid Arthritis
An Open-Label Extension of the Study XEN496 (Ezogabine) in Children With KCNQ2-DEE
TREC@TAMU Cancer Prevention Registry and Repository
Human Microbiome Research and Development for Overcoming Pediatric Diseases
Public Survey on Breath Testing for Health and Disease
Evaluation of Efficacy of Skål Pro Powder on Symptoms of Irritable Bowel Syndrome
Multi-Disciplinary Treatment on the Anthropomorphism of Large Language Models
XEN496 (Ezogabine) in Children With KCNQ2 Developmental and Epileptic Encephalopathy
Neuroimmune Dysfunction in Alcohol Use Disorder
Light Therapy Plus Exercise to Improve Motor, Non-Motor Symptoms and QoL in Parkinson's Disease
Multifamily Group Psychoeducation for SUD's in Turkey
Biomarkers of Acrylamide, Glycidol, POPs, PFAS and Disease Outcomes and OMICs Signatures
Effects of Touch on Brain Connectivity and Metabolic Biomarkers in Preterm Infants
Contribution of SuPAR for Patients in a Situation of Uncertainty Downstream of Emergencies
Outcome of Children Born After Pregnancy Denial
Novel MRI Sequence- MR Fingerprinting
European Registry for Hemadsorption in Sepsis With the Seraph Filter
The Acceptability of a Real-time Localization for Patients and Caregivers